Jagsonpal Pharma

{
  "main_header": {
    "sid": 134241,
    "name": "Jagsonpal Pharma",
    "stock_name": "Jagsonpal Pharma",
    "full_name": "Jagsonpal Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/jagsonpal-pharma",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "232.77",
    "chg": 0.88,
    "chgp": "0.38%",
    "dir": 1,
    "prev_price": "231.89",
    "mcapval": "1,544.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 507789,
    "symbol": "JAGSNPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE048B01035",
    "curr_date": "Jul 10, 03:30 PM",
    "curr_time": "18:15 PM",
    "last_traded_at": "Jul 10, 03:30 PM IST",
    "bse_nse_vol": "60.45 k",
    "exc_status": "Active",
    "traded_date": "Jul 10, 2026",
    "traded_date_str": "2026 07 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jagsonpal-pharma-134241-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Jagsonpal Pharmaceuticals Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4091655",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/JagsonpalPharma_mojoScore_4091655.png",
        "date": "2026-07-07 08:21:19",
        "description": "Jagsonpal Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a combination of deteriorating financial trends, expensive valuation metrics, and a shift in technical indicators. Despite some long-term outperformance relative to the Sensex, recent quarterly results and technical signals have prompted a reassessment of the stock’s outlook."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4091158",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/JagsonpalPharma_technicaldot_4091158.png",
        "date": "2026-07-07 08:00:21",
        "description": "Jagsonpal Pharmaceuticals Ltd has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a modest day gain of 0.36%, the stock’s technical indicators present a nuanced picture, with some metrics signalling strength while others suggest caution. This article analyses the recent technical developments, placing them in the context of the company’s price performance and broader market trends."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-ltd-is-rated-hold-4076835",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_mojoScore_4076835.png",
        "date": "2026-06-29 10:10:48",
        "description": "Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 June 2026. While this rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 29 June 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and market performance."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Gains 0.74%: 5 Key Factors Driving the Week's Mixed Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-gains-074-5-key-factors-driving-the-weeks-mixed-momentum-4066348",
        "imagepath": "",
        "date": "2026-06-21 16:00:54",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>15 Jun:</strong> Golden Cross formation signals potential bullish breakout</p>\n                    <p><strong>15 Jun:</strong> Upgrade from Strong Sell to Sell on technical improvements</p>\n                    <p><strong>17 Jun:</strong> Technical momentum shifts to bullish despite price dip</p>\n                    <p><strong>18 Jun:</strong> Upgrade from Sell to Hold amid improving technicals</p>\n                    <p><strong>19 Jun:</strong> Stock closes at Rs.212.35, up 1.00% on high volume</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.210.80</div>..."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Upgraded to Hold on Technical Improvement Despite Financial Setbacks",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-upgraded-to-hold-on-technical-improvement-despite-financial-setbacks-4060551",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_mojoScore_4060551.png",
        "date": "2026-06-18 08:10:26",
        "description": "Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Hold as of 17 June 2026, driven primarily by a marked improvement in technical indicators despite recent negative financial results. The company’s micro-cap status and mixed fundamental signals have led to a cautious stance, with the upgrade reflecting a nuanced balance between valuation, quality, financial trends, and technical momentum."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-4057949",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_technicaldot_4057949.png",
        "date": "2026-06-17 08:00:19",
        "description": "Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend on the weekly charts. Despite a recent day decline of 1.95%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse before making decisions."
      },
      {
        "title": "Golden Cross Confirmed: Do Jagsonpal Pharmaceuticals Ltd's Other Technical Indicators Agree?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-forms-golden-cross-signalling-potential-bullish-breakout-4054638",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_goldencross_4054638.png",
        "date": "2026-06-15 18:00:13",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Jagsonpal Pharmaceuticals Ltd, signalling a golden cross on 15 Jun 2026. Yet, the broader technical and fundamental context presents a nuanced picture that calls for a closer look at the reliability of this signal."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Upgraded to Sell on Technical Improvements Despite Financial Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-upgraded-to-sell-on-technical-improvements-despite-financial-challenges-4053545",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_mojoScore_4053545.png",
        "date": "2026-06-15 08:04:18",
        "description": "Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 12 June 2026, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The company’s Mojo Score rose to 42.0, reflecting a more positive technical outlook, although fundamental concerns remain. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd Shows Mixed Technical Signals Amid Mildly Bullish Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-shows-mixed-technical-signals-amid-mildly-bullish-momentum-4053306",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/JagsonpalPharma_technicaldot_4053306.png",
        "date": "2026-06-15 08:00:13",
        "description": "Jagsonpal Pharmaceuticals Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish trend on weekly charts, despite mixed signals across monthly indicators. The micro-cap pharmaceutical company’s recent price action and technical parameters suggest cautious optimism for investors, even as the MarketsMOJO rating remains a Sell with a recent upgrade from Strong Sell."
      }
    ],
    "total": 271,
    "sid": "134241",
    "stock_news_url": "https://www.marketsmojo.com/news/jagsonpal-pharmaceuticals-134241"
  },
  "announcements": [
    {
      "details": "Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr ASHOK KUMAR PATI as Additional Non-Executive Independent Director of the company w.e.f. November 14, 2019.",
      "source": "NSE",
      "caption": "Jagsonpal Pharmaceuticals Limited - Appointment",
      "datetime": "18-Nov-2019"
    },
    {
      "details": "Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 14, 2019.",
      "source": "NSE",
      "caption": "Jagsonpal Pharmaceuticals Limited - Outcome of Board Meeting",
      "datetime": "15-Nov-2019"
    },
    {
      "details": " <table><tr><td>The Exchange had sought clarification from Jagsonpal Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is enclosed. </td></tr></table>",
      "source": "NSE",
      "caption": "Reply to Clarification- Financial results",
      "datetime": "19-Sep-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has declared <strong>125%</strong> dividend, ex-date: 12 Sep 25",
          "dt": "2025-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has announced <strong>2:5</strong> stock split, ex-date: 08 Jan 25",
          "dt": "2025-01-08",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Jagsonpal Pharmaceuticals Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-07-07 08:21:19

Jagsonpal Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a combination of deteriorating financial trends, expensive valuation metrics, and a shift in technical indicators. Despite some long-term outperformance relative to the Sensex, recent quarterly results and technical signals have prompted a reassessment of the stock’s outlook.

Read full news article

Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-07-07 08:00:21

Jagsonpal Pharmaceuticals Ltd has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a modest day gain of 0.36%, the stock’s technical indicators present a nuanced picture, with some metrics signalling strength while others suggest caution. This article analyses the recent technical developments, placing them in the context of the company’s price performance and broader market trends.

Read full news article

Jagsonpal Pharmaceuticals Ltd is Rated Hold

2026-06-29 10:10:48

Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 June 2026. While this rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 29 June 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and market performance.

Read full news article

Jagsonpal Pharmaceuticals Gains 0.74%: 5 Key Factors Driving the Week's Mixed Momentum

2026-06-21 16:00:54

Key Events This Week

15 Jun: Golden Cross formation signals potential bullish breakout

15 Jun: Upgrade from Strong Sell to Sell on technical improvements

17 Jun: Technical momentum shifts to bullish despite price dip

18 Jun: Upgrade from Sell to Hold amid improving technicals

19 Jun: Stock closes at Rs.212.35, up 1.00% on high volume

Week Open

Rs.210.80

...

Read full news article

Jagsonpal Pharmaceuticals Upgraded to Hold on Technical Improvement Despite Financial Setbacks

2026-06-18 08:10:26

Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Hold as of 17 June 2026, driven primarily by a marked improvement in technical indicators despite recent negative financial results. The company’s micro-cap status and mixed fundamental signals have led to a cautious stance, with the upgrade reflecting a nuanced balance between valuation, quality, financial trends, and technical momentum.

Read full news article

Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-06-17 08:00:19

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend on the weekly charts. Despite a recent day decline of 1.95%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse before making decisions.

Read full news article

Golden Cross Confirmed: Do Jagsonpal Pharmaceuticals Ltd's Other Technical Indicators Agree?

2026-06-15 18:00:13

The 50-day moving average has crossed above the 200-day moving average for Jagsonpal Pharmaceuticals Ltd, signalling a golden cross on 15 Jun 2026. Yet, the broader technical and fundamental context presents a nuanced picture that calls for a closer look at the reliability of this signal.

Read full news article

Jagsonpal Pharmaceuticals Upgraded to Sell on Technical Improvements Despite Financial Challenges

2026-06-15 08:04:18

Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 12 June 2026, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The company’s Mojo Score rose to 42.0, reflecting a more positive technical outlook, although fundamental concerns remain. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change.

Read full news article

Jagsonpal Pharmaceuticals Ltd Shows Mixed Technical Signals Amid Mildly Bullish Momentum

2026-06-15 08:00:13

Jagsonpal Pharmaceuticals Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish trend on weekly charts, despite mixed signals across monthly indicators. The micro-cap pharmaceutical company’s recent price action and technical parameters suggest cautious optimism for investors, even as the MarketsMOJO rating remains a Sell with a recent upgrade from Strong Sell.

Read full news article

View All News